Regulatory FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients FDAThe U.S.Gene Therapy PlatformRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) FDA The U.S. Gene Therapy Platform Read full story Post navigation Previous: ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay offNext: ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026